Enliven Therapeutics Inc (ELVN) Stock Price, Quote & News

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 647 8519

Website: www.enliventherapeutics.com

Address:

6200 Lookout Road, Boulder, United States

thedentite Jun. 23 at 4:20 PM

$ELVN Yet another amazing day!

0 · Reply

thedentite Jun. 22 at 2:52 PM

$ELVN Why is sentiment bearish on this stock? Who can possibly be bearish?

0 · Reply

thedentite Jun. 22 at 2:20 PM

$ELVN Great day for $ALT and $ELVN!

0 · Reply

Doozio Jun. 17 at 9:17 PM

$ELVN they ain’t CHSN. They SKWD. All da way up da Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

thedentite Jun. 17 at 6:43 PM

$ELVN Now we just have to avoid that sudden BS dump at the close that we had yesterday. If that happens I am going to start swing-trading a chunk every day.

0 · Reply

TheRealiSwag Jun. 17 at 2:19 PM

$VSTM just a few days away from potentially steamrolling 25% short of the float on data. After getting cut down from $11 to under $4 in 8 months, its time to cover as the smart business practice takes over from here. High risk/high reward here folks. Also watching $EVMN for data any day now, one of Bairds leading candidates for M&A targets this year fwiw. $ELVN has been best in class following TERN before they were taken out. $XBI keep the momentum intact!

0 · Reply

thedentite Jun. 16 at 4:21 PM

$ELVN Nice movement here, just picked up another 300 shares. on the dip.

0 · Reply

blue81 Jun. 16 at 6:37 AM

$ELVN soon btd 60 $ after August

1 · Reply

thedentite Jun. 14 at 7:53 PM

$ALT As much as I love ya'll, I'm seeing someone else. $ELVN is the woman I keep wanting $ALT to be. Half my money is here, half is there. I keep thinking something will happen here, but things ARE happening there.

2 · Reply

Spicy_Trade Jun. 14 at 6:27 PM

Enliven Therapeutics, Inc. ( $ELVN ) SpicyTrade - Daily Stock Analysis https://youtu.be/umrswruzsXo?si=T7kjnnL86gAydsuO

0 · Reply

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

2026-06-12T18:22:53.000Z - 11 days ago

Why Is Enliven Therapeutics Stock (ELVN) Up Today?

2026-06-12T16:08:54.000Z - 11 days ago

Enliven rises 9.9%

Jun 11, 2026, 10:39 PM EDT - 12 days ago

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

2026-06-11T20:14:01.000Z - 12 days ago

Enliven announces $250M common stock offering

Jun 11, 2026, 4:05 PM EDT - 12 days ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-06-11T14:08:06.000Z - 12 days ago

Enliven rises 14.8%

Jun 11, 2026, 8:30 AM EDT - 12 days ago

Enliven Therapeutics Transcript: Study update

Jun 11, 2026, 8:30 AM EDT - 12 days ago

Enliven Therapeutics Press release: Study update

Jun 11, 2026, 8:30 AM EDT - 12 days ago

Enliven Therapeutics Slides: Study update

2026-06-11T12:17:12.000Z - 12 days ago

Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial

2026-06-11T12:11:48.000Z - 12 days ago

Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial

Jun 11, 2026, 8:00 AM EDT - 12 days ago

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

2026-06-08T20:18:26.000Z - 15 days ago

Enliven initiated with a Buy at Stifel

Jun 4, 2026, 11:40 AM EDT - 19 days ago

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:05 PM EDT - 20 days ago

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

2026-06-02T11:19:14.000Z - 21 days ago

Enliven price target raised to $62 from $45 at Mizuho

May 27, 2026, 2:30 PM EDT - 27 days ago

Enliven Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 4:05 PM EDT - 4 weeks ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

2026-05-12T19:08:09.000Z - 6 weeks ago

Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress

May 12, 2026, 9:53 AM EDT - 6 weeks ago

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

2026-05-12T08:45:09.000Z - 6 weeks ago

Guggenheim starts Enliven with Buy on leukemia opportunity

2026-05-12T00:30:09.000Z - 6 weeks ago

Enliven initiated with a Buy at Guggenheim

2026-05-08T18:30:31.000Z - 6 weeks ago

Enliven price target raised to $59 from $41 at Goldman Sachs

May 7, 2026, 4:05 PM EDT - 6 weeks ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Enliven Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Enliven Therapeutics Earnings release: Q1 2026

2026-04-30T19:32:47.000Z - 7 weeks ago

Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho

MRK TERN

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Enliven Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Enliven Therapeutics Proxy statement: Proxy filing

2026-04-27T09:20:09.000Z - 2 months ago

Enliven price target raised to $55 from $36 at Clear Street

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Enliven Therapeutics Proxy statement: Proxy filing

2026-03-26T16:07:38.000Z - 3 months ago

Enliven rises 11.0%

2026-03-26T10:21:09.000Z - 3 months ago

Enliven price target raised to $56 from $48 at H.C. Wainwright

Mar 3, 2026, 3:00 PM EST - 4 months ago

Enliven Therapeutics Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 4 months ago

Enliven Therapeutics Earnings release: Q4 2025

Mar 3, 2026, 10:30 AM EST - 4 months ago

Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 4 months ago

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Jan 8, 2026, 9:00 AM EST - 5 months ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 7, 2026, 9:00 AM EST - 5 months ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Dec 11, 2025, 4:21 PM EST - 6 months ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Dec 11, 2025, 9:00 AM EST - 6 months ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Nov 18, 2025, 11:00 AM EST - 7 months ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 7 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 12, 2025, 7:00 AM EST - 7 months ago

Enliven Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Enliven Therapeutics Quarterly report: Q3 2025

Aug 25, 2025, 6:20 PM EDT - 10 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Enliven Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Enliven Therapeutics Earnings release: Q2 2025

Jun 16, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Press release: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Slides: Study Update

Jun 13, 2025, 9:30 AM EDT - 1 year ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:02 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 1:00 PM EDT - 1 year ago

Enliven Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q1 2025

May 14, 2025, 9:56 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 2, 2025, 4:03 PM EDT - 1 year ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Annual report: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 10:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Nov 19, 2024, 4:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Enliven Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q2 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

Enliven Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Registration statement: Registration Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Study Update

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Slides: Study Update

Apr 11, 2024, 7:55 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q4 2023

Feb 29, 2024, 6:00 PM EST - 2 years ago

Enliven Therapeutics Slides: Investor Presentation

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Nov 8, 2023, 6:00 PM EST - 2 years ago

Enliven Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Enliven Therapeutics Earnings release: Q3 2023

Aug 10, 2023, 4:05 PM EDT - 3 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q2 2023

Jun 23, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Registration statement: Registration Filing

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q1 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

Feb 10, 2023, 7:00 AM EST - 3 years ago

Enliven Therapeutics Annual report: Q4 2022

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Transcript: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Press release: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Slides: M&A Announcement

Oct 13, 2022, 4:35 PM EDT - 4 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 7, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Sep 23, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Sep 7, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Annual report: Q4 2021

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 5, 2022, 7:00 AM EST - 4 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Dec 14, 2021, 7:00 AM EST - 4 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Nov 22, 2021, 7:00 AM EST - 4 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

thedentite Jun. 23 at 4:20 PM

$ELVN Yet another amazing day!

0 · Reply

thedentite Jun. 22 at 2:52 PM

$ELVN Why is sentiment bearish on this stock? Who can possibly be bearish?

0 · Reply

thedentite Jun. 22 at 2:20 PM

$ELVN Great day for $ALT and $ELVN!

0 · Reply

Doozio Jun. 17 at 9:17 PM

$ELVN they ain’t CHSN. They SKWD. All da way up da Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

thedentite Jun. 17 at 6:43 PM

$ELVN Now we just have to avoid that sudden BS dump at the close that we had yesterday. If that happens I am going to start swing-trading a chunk every day.

0 · Reply

TheRealiSwag Jun. 17 at 2:19 PM

0 · Reply

thedentite Jun. 16 at 4:21 PM

$ELVN Nice movement here, just picked up another 300 shares. on the dip.

0 · Reply

blue81 Jun. 16 at 6:37 AM

$ELVN soon btd 60 $ after August

1 · Reply

thedentite Jun. 14 at 7:53 PM

2 · Reply

Spicy_Trade Jun. 14 at 6:27 PM

Enliven Therapeutics, Inc. ( $ELVN ) SpicyTrade - Daily Stock Analysis https://youtu.be/umrswruzsXo?si=T7kjnnL86gAydsuO

0 · Reply

topstockalerts Jun. 12 at 10:09 PM

$ELVN this could catch a few people sleeping

0 · Reply

RunnerSignals Jun. 12 at 8:25 PM

market warriors $ELVN reversed from open on 5.8x volume - accumulation confirmed, not a squeeze $KLAC late session bid holding near highs follow-through setup tomorrow

0 · Reply

StocktwitsNews Jun. 12 at 6:22 PM

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development $ELVN $VTI $IWM https://stocktwits.com/news/equity/markets/elvn-stock-on-track-for-best-week-since-march/cZKd3s0R75a

0 · Reply

FonsieTrader Jun. 12 at 5:59 PM

$ELVN Sometimes the biggest moves start when a chart stops asking for permission. Multi-month consolidation. Higher lows. Breakout. Volume expansion. Strong relative strength. Now price is beginning to separate itself from the base. This looks like the start of a new trend, not the end of one. Definitely on my radar.

1 · Reply

Dont_hate Jun. 12 at 5:20 PM

$ELVN

1 · Reply

mhoward1711 Jun. 12 at 3:10 PM

$ELVN

0 · Reply

thedentite Jun. 12 at 3:04 PM

$ELVN Why is no one posting gifs of rockets?

0 · Reply

BobBobbertonnn Jun. 12 at 3:04 PM

$ELVN Would think a 3B+ EV is justifiable here. Add in cash. Still seems like theres some room to run on price on a post-financing fully diluted basis 🤷🏼‍♂️

0 · Reply

thedentite Jun. 12 at 2:26 PM

$ELVN What a lovely friday! We are going to fly.

0 · Reply

thedentite Jun. 11 at 3:21 PM

$ELVN Being up 10% - super happy. Being up 20% and then down to 10%.... feels about the same as simply being down 10%.

1 · Reply

Dark_Tape Jun. 11 at 3:17 PM

$ELVN dilution is the solution 🩸🩸 $SPY $QQQ

0 · Reply

Market Cap	2.80B
Revenue (ttm)	0.00
Net Income (ttm)	-103.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,981,900
Avg Vol	1,183,712
Day's Range	N/A - N/A
Shares Out	60.91M
Stochastic %K	99%
Beta	0.29
Analysts	Strong Sell
Price Target	$58.80